X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19747) 19747
Newsletter (556) 556
Newspaper Article (98) 98
Book Chapter (66) 66
Dissertation (40) 40
Conference Proceeding (22) 22
Magazine Article (13) 13
Publication (13) 13
Streaming Video (3) 3
Transcript (3) 3
Book Review (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gemcitabine (17547) 17547
humans (11954) 11954
oncology (10507) 10507
chemotherapy (8665) 8665
cancer (7165) 7165
female (6946) 6946
male (6049) 6049
pancreatic cancer (6028) 6028
deoxycytidine - analogs & derivatives (5940) 5940
middle aged (5692) 5692
aged (5591) 5591
adult (4035) 4035
antineoplastic combined chemotherapy protocols - therapeutic use (4025) 4025
cisplatin (3649) 3649
survival (3460) 3460
deoxycytidine - administration & dosage (3397) 3397
treatment outcome (3306) 3306
care and treatment (2862) 2862
pancreatic neoplasms - drug therapy (2727) 2727
adenocarcinoma (2691) 2691
research (2542) 2542
therapy (2491) 2491
pancreatic neoplasms - pathology (2462) 2462
carcinoma (2253) 2253
metastasis (2226) 2226
aged, 80 and over (2181) 2181
lung neoplasms - drug therapy (2112) 2112
pharmacology & pharmacy (2078) 2078
prognosis (2056) 2056
paclitaxel (2041) 2041
trial (2040) 2040
animals (2024) 2024
cell line, tumor (1984) 1984
tumors (1892) 1892
combination (1843) 1843
carcinoma, non-small-cell lung - drug therapy (1830) 1830
deoxycytidine - therapeutic use (1795) 1795
surgery (1749) 1749
neoplasm staging (1698) 1698
antineoplastic combined chemotherapy protocols - adverse effects (1685) 1685
analysis (1682) 1682
cancer therapies (1680) 1680
apoptosis (1652) 1652
medicine & public health (1547) 1547
phase-iii trial (1527) 1527
expression (1506) 1506
survival rate (1489) 1489
antineoplastic agents - therapeutic use (1484) 1484
carboplatin (1476) 1476
disease-free survival (1459) 1459
survival analysis (1444) 1444
health aspects (1429) 1429
deoxycytidine - adverse effects (1424) 1424
retrospective studies (1379) 1379
drug therapy (1374) 1374
phase-ii trial (1366) 1366
clinical trials (1362) 1362
mice (1353) 1353
phase-ii (1310) 1310
radiotherapy (1309) 1309
patients (1306) 1306
docetaxel (1305) 1305
deoxycytidine - pharmacology (1288) 1288
cisplatin - administration & dosage (1215) 1215
gastroenterology & hepatology (1203) 1203
lung neoplasms - pathology (1164) 1164
antineoplastic agents (1133) 1133
medical prognosis (1125) 1125
adenocarcinoma - drug therapy (1121) 1121
lung cancer (1095) 1095
toxicity (1061) 1061
antimetabolites, antineoplastic - therapeutic use (1058) 1058
oncology, experimental (1056) 1056
pancreatic neoplasms - mortality (1041) 1041
antimitotic agents (1029) 1029
hematology, oncology and palliative medicine (1005) 1005
5-fluorouracil (994) 994
combined modality therapy (992) 992
drug administration schedule (968) 968
oxaliplatin (953) 953
pancreatic neoplasms - therapy (948) 948
carcinoma, non-small-cell lung - pathology (941) 941
lung cancer, non-small cell (909) 909
vinorelbine (889) 889
antineoplastic combined chemotherapy protocols - administration & dosage (882) 882
doxorubicin (882) 882
multicenter (881) 881
cell lung-cancer (873) 873
dose-response relationship, drug (859) 859
metastases (845) 845
non-small cell lung cancer (840) 840
adjuvant chemotherapy (836) 836
pancreatic neoplasms - metabolism (834) 834
adenocarcinoma - pathology (830) 830
respiratory system (802) 802
studies (788) 788
kaplan-meier estimate (778) 778
antimetabolites, antineoplastic - administration & dosage (776) 776
disease progression (774) 774
pancreas (772) 772
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19817) 19817
French (261) 261
German (239) 239
Japanese (177) 177
Chinese (72) 72
Korean (62) 62
Spanish (62) 62
Italian (21) 21
Portuguese (18) 18
Polish (15) 15
Russian (12) 12
Turkish (10) 10
Czech (6) 6
Hungarian (4) 4
Norwegian (3) 3
Persian (3) 3
Slovak (3) 3
Catalan (2) 2
Romanian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Synlett, ISSN 0936-5214, 08/2014, Volume 25, Issue 13, pp. 1851 - 1854
Journal Article
International journal of pharmaceutics, ISSN 0378-5173, 01/2015, Volume 478, Issue 1, p. 308
Display Omitted 
Gemcitabine
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 08/2017, Volume 15, Issue 8, pp. 1028 - 1028
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between... 
PHASE-III TRIAL | ADJUVANT CHEMOTHERAPY | FINE-NEEDLE-ASPIRATION | ONCOLOGY | BILIARY DRAINAGE | GEMCITABINE-BASED CHEMORADIATION | PACLITAXEL PLUS GEMCITABINE | FULL-DOSE GEMCITABINE | QUALITY-OF-LIFE | EUS-GUIDED FNA | RADIATION-THERAPY
Journal Article
Der Onkologe, ISSN 0947-8965, 05/2019, Volume 25, Issue 5, p. 466
Journal Article
Cancer, ISSN 0008-543X, 2015, Volume 121, Issue 5, pp. 673 - 680
Journal Article
Chirurg, ISSN 0009-4722, 10/2016, Volume 87, Issue 10, p. 892
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00104-016-0282-2 
Gemcitabine
Journal Article
Gastroenterology clinics of North America, ISSN 0889-8553, 03/2012, Volume 41, Issue 1, pp. 189 - 209
Journal Article
The Surgical clinics of North America, ISSN 0039-6109, 12/2016, Volume 96, Issue 6, pp. 1391 - 1414
Journal Article
by Wang-Gillam, Andrea and Li, Chung-Pin and Bodoky, György and Dean, Andrew and Shan, Yan-Shen and Jameson, Gayle and Macarulla, Teresa and Lee, Kyung-Hun and Cunningham, David and Blanc, Jean F and Hubner, Richard A and Chiu, Chang-Fang and Schwartsmann, Gilberto and Siveke, Jens T and Braiteh, Fadi and Moyo, Victor and Belanger, Bruce and Dhindsa, Navreet and Bayever, Eliel and Von Hoff, Daniel D and Chen, Li-Tzong and Adoo, Clarence and Anderson, Thomas and Asselah, Jamil and Azambuja, Alan and Bampton, Carolyn and Barrios, Carlos Henrique and Bekaii-Saab, Tanios and Bohuslav, Melichar and Chang, David and Chen, Jen-Shi and Chen, Yeu-Chin and Choi, Hye Jin and Chung, Ik Joo and Chung, Vincent and Csoszi, Tibor and Cubillo, Antonio and DeMarco, Linda and de Wit, Maike and Dragovich, Tomislav and Edenfield, William and Fein, Luis Enrique and Franke, Fábio and Fuchs, Martin and Gonzales-Cruz, Vega and Gozza, Alberto and Fernando, Rivera Herrero and Iaffaioli, Rosario and Jakesova, Jitka and Kahan, Zsuzsanna and Karimi, Misagh and Kim, Jun Suk and Korbenfeld, Ernesto and Lang, Istvan and Lee, Fa-Chyi and Lee, Kuan-Der and Lipton, Lara and Ma, Wen Wee and Mangel, Laszlo and Mena, Raul and Palmer, Daniel and Pant, Shubham and Park, Joon Oh and Piacentini, Paolo and Pelzer, Uwe and Plazas, Javier Gallego and Prasad, Cooray and Rau, Kun-Ming and Raoul, Jean-Luc and Richards, Donald and Ross, Paul and Schlittler, Luis and Smakal, Martin and Stahalova, Vladimira and Sternberg, Cora and Seufferlein, Thomas and Tebbutt, Niall and Vinholes, Jeferson Jose and Wadlow, Raymond and Wenczl, Milkos and Wong, Mark and NAPOLI-1 Study Group and NAPOLI-1 Study Grp
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10018, pp. 545 - 557
Summary Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated... 
Internal Medicine | PLUS GEMCITABINE | SURVIVAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | ADENOCARCINOMA | 2ND-LINE CHEMOTHERAPY | OXALIPLATIN | PEP02 | DOCETAXEL | CARCINOMA | FOLFIRI | Leucovorin - administration & dosage | Humans | Middle Aged | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Irinotecan | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Liposomes | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Pancreatic cancer | Leucovorin | Product development | Research institutes | Metastasis | Antineoplastic agents | Analysis | Antigens | Chemotherapy | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Tumors | Adenocarcinoma | Therapy | Gemcitabine | Toxicity | Evidence-based medicine | Metastases | Nanoparticles | Randomization | Vomiting | Safety management | Toxic diseases | Neutropenia | Folinic acid | Lymphatic system | Medical treatment | Diarrhea | FDA approval | Survival | Patients | Acids | Equivalence | Interactive systems
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. S1269 - S1269
Journal Article
Journal Article
Journal Article
ONCOLOGY REPORTS, ISSN 1021-335X, 05/2010, Volume 23, Issue 5, pp. 1183 - 1192
Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of... 
targeted therapies | COMPARING GEMCITABINE | MONOCLONAL-ANTIBODY | FOLINIC ACID | ERLOTINIB PLUS GEMCITABINE | capecitabine | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | 2ND-LINE THERAPY | ONCOLOGY | DOSE-RATE GEMCITABINE | platinum compounds | COMBINATION CHEMOTHERAPY | gemcitabine | advanced pancreatic cancer | COOPERATIVE-ONCOLOGY-GROUP | Carcinoma, Pancreatic Ductal - secondary | Pancreatic Neoplasms - metabolism | Humans | Carcinoma, Pancreatic Ductal - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Palliative Care | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Angiogenesis Inhibitors - administration & dosage | Deoxycytidine - therapeutic use | Fluorouracil - administration & dosage | Deoxycytidine - adverse effects | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - pathology | Treatment Outcome | Clinical Trials as Topic | Evidence-Based Medicine | Carcinoma, Pancreatic Ductal - drug therapy | Protein Kinase Inhibitors - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Deoxycytidine - analogs & derivatives
Journal Article